The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.
Pakvisal N, Wongkongkathep P, Bunrasmee W, Sodsai P, Siriluksana J, Boonnak N, Sangcharoen T, Trakarnsanga B, Sukprakun S, Wantanasiri P, Chotirosniramit K, Phanichkrivalkosil M, Nanthawong S, Chanchaem P, Mankhong S, Kumpunya S, Supabphol S, Sirijun N, Kongtragulsub K, Pearngam P, Somparn P, Payne DM, Zhao B, Praphanphoj V, Pornputtapong N, Sriswasdi S, Wichadakul D, Uttamapinan S, Angspatt P, Wongchanapat P, Teeyapun N, Luangdilok S, Sitthideatphaiboon P, Susiriwatananont T, Zungsontiporn N, Parinyanitikul N, Tanasanvimon S, Vinayanuwattikun C, Salazar A, Hirankarn N, Sriuranpong V, Pisitkun T.
Pakvisal N, et al. Among authors: phanichkrivalkosil m.
Clin Cancer Res. 2026 Aug 3;32(15):3213-3227. doi: 10.1158/1078-0432.CCR-25-4271.
Clin Cancer Res. 2026.
PMID: 42095629
Clinical Trial.